Related references
Note: Only part of the references are listed.First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos et al.
ONCOLOGIST (2021)
Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors
Jian Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Hospital -based or home -based administration of oncology drugs? A micro -costing study comparing healthcare and societal costs of hospital -based and home -based subcutaneous administration of trastuzumab
Margreet Franken et al.
BREAST (2020)
Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors
Yutaka Fujiwara et al.
CANCER SCIENCE (2019)
Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics
Kenneth C. Anderson et al.
FUTURE ONCOLOGY (2019)
Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands
Margreet G. Franken et al.
ANTI-CANCER DRUGS (2018)
Subcutaneous delivery of monoclonal antibodies: How do we get there?
Margarida Viola et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors
Noboru Yamamoto et al.
INVESTIGATIONAL NEW DRUGS (2017)
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
Pieternella Lugtenburg et al.
HAEMATOLOGICA (2017)
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
Christopher R. Heery et al.
LANCET ONCOLOGY (2017)
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study
Pieternella Lugtenburg et al.
HAEMATOLOGICA (2017)
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
Andrew Davies et al.
LANCET HAEMATOLOGY (2017)
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade
Fei Zhang et al.
CELL DISCOVERY (2017)
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
Toshio Shimizu et al.
INVESTIGATIONAL NEW DRUGS (2016)
Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors
Hidenori Mizugaki et al.
INVESTIGATIONAL NEW DRUGS (2016)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial
Maximilian Merz et al.
HAEMATOLOGICA (2015)
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial
Maximilian Merz et al.
HAEMATOLOGICA (2015)
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
Gustavo Ismael et al.
LANCET ONCOLOGY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau et al.
LANCET ONCOLOGY (2011)
Share Paper
